Lisata Therapeutics extends deadline for Kuva tender offer

Lisata Therapeutics ( (LSTA) ) just unveiled an announcement.

On April 2, 2026, Lisata Therapeutics and Kuva Labs agreed to extend the deadline for Kuva’s subsidiary to launch a tender offer to acquire all outstanding Lisata common shares, moving the date from April 3 to April 13, 2026, or another mutually agreed date. The tender offer, tied to a March 6, 2026 merger agreement, has not yet started as Kuva is still seeking more favorable financing, and Lisata is actively discussing funding and timing with Kuva while cautioning that there is no assurance the tender offer will commence.

Lisata emphasized that the tender offer has not begun and that any future offer would be made only through official documents filed with the U.S. Securities and Exchange Commission, which will be provided free to shareholders if the process moves forward. The company urged investors to carefully review these materials, including the anticipated tender offer statement and Lisata’s recommendation statement, before deciding whether to tender their shares, underscoring continued uncertainty around the proposed transaction’s timing and completion.

The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Spark’s Take on LSTA Stock

According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.

The score is held back primarily by weak financial performance (limited/volatile revenue, persistent losses, and ongoing cash burn), partially offset by a strong technical uptrend and a value-defining acquisition agreement with additional contingent upside. Valuation is neutral-to-weak given negative earnings and no dividend information.

To see Spark’s full report on LSTA stock, click here.

More about Lisata Therapeutics

Lisata Therapeutics, Inc. is a biopharmaceutical company whose shares of common stock are publicly traded, making its investors and stockholders subject to corporate actions such as tender offers and merger agreements. The company is currently the target in a planned acquisition structure involving a parent entity, Kuva Labs Inc., and its wholly owned subsidiary, Kuva Acquisition Corp., which intends to purchase all outstanding Lisata shares through a tender offer.

Average Trading Volume: 182,049

Technical Sentiment Signal: Hold

Current Market Cap: $45.07M

For an in-depth examination of LSTA stock, go to TipRanks’ Overview page.